Bionime Corporation completed the Taiwan clinical trial and got a Taiwan clinical study report for Continuous Glucose Monitoring System. The Company will prepare the relevant documents to submit the clinical study report of CGM products to TFDA for registration submission and to get product certificate. Afterwards, the Company will start international clinical strategies in planned sites, followed by getting approval in different regions.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
68.8 TWD | -0.58% | -0.15% | -8.02% |
Mar. 15 | Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 14 | Bionime Corporation Announces Dividend for the Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.02% | 129M | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.3B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B | |
-5.02% | 1.64B |
- Stock Market
- Equities
- 4737 Stock
- News Bionime Corporation
- Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System